Meng and colleagues demonstrated that SGLT2 inhibition using empagliflozin attenuates inflammatory responses via modulating IL-17/IL-23 and AMPK/mTOR (AMP-activated protein kinase/mammalian target of rapamycin) signaling pathways, and improves liver sufficiency in HFD (high-fat diet) C57BL/6J mice with NAFLD (Meng et al., 2021[58]). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.